Sign up to save your podcasts
Or
Share Treatment optimization in mCRC: third-line and beyond
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treatment optimization in mCRC: third-line and beyond
Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible. Do you know how to sequence later line therapies in metastatic colorectal cancer?
In this podcast, gastrointestinal oncologists Dr Thomas Winder (Austria and Switzerland) and Dr Mark Lewis (USA) discuss the treatment of metastatic colorectal cancer, third line and beyond. They discuss the sequence of later line treatments regorafenib, TAS-102, bevacizumab and fruquintinib and refer to key clinical trials such as SUNLIGHT, CORRECT, RECOURSE, FRESCO-2 and ReDOS. They emphasise the importance of balancing treatment efficacy whilst considering adverse event profiles to maintain the patient’s quality of life.
The experts also discuss biomarkers used in a number of molecularly selected trials such as HER2 in the HERACLES (trastuzumab plus lapatininb), MOUNTAINEER (tucatinib plus trastuzumab) and DESTINY-CRC02 (trastuzumab deruxtecan) studies and KRAS G12c in the CODEBREAK 300 study (sotorasib plus panitumumab).
View all episodes
By COR2ED Medical EducationTreatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible. Do you know how to sequence later line therapies in metastatic colorectal cancer?
In this podcast, gastrointestinal oncologists Dr Thomas Winder (Austria and Switzerland) and Dr Mark Lewis (USA) discuss the treatment of metastatic colorectal cancer, third line and beyond. They discuss the sequence of later line treatments regorafenib, TAS-102, bevacizumab and fruquintinib and refer to key clinical trials such as SUNLIGHT, CORRECT, RECOURSE, FRESCO-2 and ReDOS. They emphasise the importance of balancing treatment efficacy whilst considering adverse event profiles to maintain the patient’s quality of life.
The experts also discuss biomarkers used in a number of molecularly selected trials such as HER2 in the HERACLES (trastuzumab plus lapatininb), MOUNTAINEER (tucatinib plus trastuzumab) and DESTINY-CRC02 (trastuzumab deruxtecan) studies and KRAS G12c in the CODEBREAK 300 study (sotorasib plus panitumumab).